BidaskClub upgraded shares of G1 Therapeutics (NASDAQ:GTHX) from a sell rating to a hold rating in a report published on Wednesday morning.
Several other research analysts also recently commented on GTHX. BTIG Research started coverage on G1 Therapeutics in a research report on Tuesday, December 19th. They issued a buy rating and a $38.00 price target on the stock. Zacks Investment Research cut G1 Therapeutics from a hold rating to a sell rating in a research report on Wednesday, October 11th. Finally, Cowen restated a buy rating on shares of G1 Therapeutics in a research report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $31.40.
Shares of G1 Therapeutics (GTHX) traded down $0.40 during midday trading on Wednesday, reaching $20.00. The company’s stock had a trading volume of 91,300 shares, compared to its average volume of 109,500. G1 Therapeutics has a 52 week low of $12.04 and a 52 week high of $28.67.
In other G1 Therapeutics news, major shareholder Medimmune Ventures, Inc. sold 133,906 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $19.75, for a total value of $2,644,643.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Fredric N. Eshelman purchased 250,000 shares of the stock in a transaction on Monday, November 13th. The stock was bought at an average price of $19.73 per share, for a total transaction of $4,932,500.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 541,406 shares of company stock worth $10,746,719.
A number of large investors have recently made changes to their positions in the business. Alps Advisors Inc. grew its position in G1 Therapeutics by 9.1% in the third quarter. Alps Advisors Inc. now owns 27,766 shares of the company’s stock valued at $691,000 after acquiring an additional 2,317 shares during the period. Chartwell Investment Partners LLC grew its position in G1 Therapeutics by 5.0% in the third quarter. Chartwell Investment Partners LLC now owns 92,558 shares of the company’s stock valued at $2,303,000 after acquiring an additional 4,388 shares during the period. American International Group Inc. bought a new stake in G1 Therapeutics in the third quarter valued at $130,000. California State Teachers Retirement System bought a new stake in G1 Therapeutics in the third quarter valued at $319,000. Finally, Schwab Charles Investment Management Inc. bought a new stake in G1 Therapeutics in the third quarter valued at $364,000. Hedge funds and other institutional investors own 43.25% of the company’s stock.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.